Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against Staphylococcus aureus in the Neutropenic Murine Thigh Infection Model.
We evaluated the efficacy of escalating doses of exebacase administered with sub-therapeutic daptomycin exposures against 8 Staphylococcus aureus isolates in a neutropenic murine thigh infection model. Daptomycin alone resulted in mean growth of 0.39 ± 1.19 log10CFU/thigh. Administered in addition to daptomycin, exebacase resulted in a mean log10 CFU/thigh reduction of -1.03 ± 0.72 (range: -0.77 ± 0.98 to -1.20 ± 0.59) across evaluated doses (15 to 90 mg/kg), indicative of potential in vivo synergy.